| Literature DB >> 32468277 |
Dimitrios Farmakis1,2, Christina Chrysohoou3, Gregory Giamouzis4, George Giannakoulas5, Michalis Hamilos6, Katerina Naka7, Stylianos Tzeis8, Sotirios Xydonas9, Apostolos Karavidas10, John Parissis11.
Abstract
Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the other. Their frequent coexistence raises several challenges, including under-diagnosis of HF with preserved ejection fraction in AF and of AF in HF, characterization and diagnosis of atrial cardiomyopathy, target and impact of rate control therapy on outcomes, optimal rhythm control strategy in the era of catheter ablation, HF-related thromboembolic risk and management of anticoagulation in patients with comorbidities, such as chronic kidney disease or transient renal function worsening, coronary artery disease or acute coronary syndromes, valvular or structural heart disease interventions and cancer. In the present document, derived by an expert panel meeting, we sought to focus on the above challenging issues, outlining the existing evidence and identifying gaps in knowledge that need to be addressed.Entities:
Keywords: Atrial fibrillation; Direct oral anticoagulants; Heart failure; Non-vitamin K antagonist oral anticoagulants; Rate control; Rhythm control
Mesh：
Substances：
Year: 2021 PMID： 32468277 DOI： 10.1007/s10741-020-09978-0
Source DB: PubMed Journal: Heart Fail Rev ISSN： 1382-4147 Impact factor: 4.214